VAM
GNMX

Verity Asset Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Verity Asset Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-30,500
Closed -$4K – 146
2019
Q4 		$4K Buy
30,500
+13,500
+79% +$1.84K ﹤0.01% 125
2019
Q3 		$3K Hold
17,000
– – ﹤0.01% 129
2019
Q2 		$3K Hold
17,000
– – ﹤0.01% 125
2019
Q1 		$3K Hold
17,000
– – ﹤0.01% 117
2018
Q4 		$12K Buy
17,000
+3,000
+21% +$3.35K 0.02% 104
2018
Q3 		$17K Buy
14,000
+2,500
+22% +$2.79K 0.02% 131
2018
Q2 		$13K Buy
11,500
+1,500
+15% +$2.28K 0.01% 113
2018
Q1 		$20K Sell
10,000
-4,500
-31% -$8.45K 0.02% 119
2017
Q4 		$28K Buy
+14,500
New +$19.8K 0.02% 129

Verity Asset Management's GNMX Position: Q1 2020 in Review

Verity Asset Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 30,500 shares — an estimated $4K sold.

Verity Asset Management first reported a position in GNMX in Q4 2017 and held it in 9 quarters. The position peaked at $28K in Q4 2017. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.

  • Verity Asset Management reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
  • Verity Asset Management sold 30,500 Aevi Genomic Medicine Inc shares in Q1 2020, an estimated $4K.
  • Verity Asset Management first reported a position in Aevi Genomic Medicine Inc in Q4 2017 and held it in 9 quarters.
  • Verity Asset Management's Aevi Genomic Medicine Inc position peaked at $28K in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.

Based on Verity Asset Management's 13F filing for Q1 2020, filed 18 May 2020.